Janssen presents positive results from phase II RSV vaccine trial

The promising phase IIb data comes shortly after the announcement of plans for a phase III trial.
Photo: Shannon Stapleton/Reuters/Ritzau Scanpix
Photo: Shannon Stapleton/Reuters/Ritzau Scanpix
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN

Janssen's vaccine against respiratory syncytial virus, known as RSV, has lived up to the company's expectations in the latest study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading